Evidence map›Paper›PMID 42177521›Full record

ArticleJournal of nanobiotechnology2026

A gas-liquid biphasic nanocleaner for breaking the self-amplified vicious cycle of barrier disruption-inflammation in inflammatory bowel disease.

Haibin Wu, Jixiang Zhang, Xinqing Huang, Bo Zhang, Yuting Xie, Qingyu Li, Li Yang, Weiqi Wu, Ziying Zheng, Ziyan Huang and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Haibin Wu *School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China. wuhaibin@hmc.edu.cn.
Jixiang Zhang *School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China.
Xinqing Huang *School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China.
Bo Zhang *Frontiers Science Center for Transformative Molecules, School of Chemistry and Chemical Engineering, School of Biomedical Engineering, National Center for Translational Medicine, Shanghai Advanced Research Institute, Shanghai Jiao Tong University, Shanghai, 200240, China.
Yuting XieSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China.
Qingyu LiSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China.
Li YangSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China.
Weiqi WuSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China.
Ziying ZhengSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China.
Ziyan HuangSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China.
Fanru GaoSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China.
Zhongqing CaiSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China.
Jiahe ChenSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China.
Guohuan ZengSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China.
Daishun LingFrontiers Science Center for Transformative Molecules, School of Chemistry and Chemical Engineering, School of Biomedical Engineering, National Center for Translational Medicine, Shanghai Advanced Research Institute, Shanghai Jiao Tong University, Shanghai, 200240, China. dsling@sjtu.edu.cn.
Guang LiangSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China. wzmcliangguang@163.com.
Qian ChenSchool of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, 311399, Zhejiang, China. chenqian08@zju.edu.cn.

Funding

HMC Seeking Truth Talent Project 00004F1RCYJ2209Institutional Special Project of the Department of Science and Technology of Zhejiang Province YS202604National Natural Science Foundation of China 32571612
6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is a chronic relapsing disorder primarily driven by the self-amplified vicious cycle of colonic barrier disruption-inflammation (VCBI). Especially, these pathogenic mediators of the VCBI often exist in different phases, such as ROS (inflammatory mediators) in the liquid phase and H

Indexed as

InflammationInflammatory Bowel DiseasesNanoparticlesAnimalsGasesHumansHydrogen PeroxideHydrogen SulfideIntestinal Barrier FunctionMiceReactive Oxygen SpeciesGasesHydrogen PeroxideHydrogen SulfideReactive Oxygen SpeciesGas-liquid biphasic nanocleanerInflammatory bowel diseaseMultiphase pathogenic factorsSelf-amplified vicious cycle

Identifiers

PMID42177521
PMCPMC13383427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.